Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Provision of Patient Services

Sponsored by

Finalist

Immunology Patient Services in IBD

MSD


Summary of work

Remicade (infliximab) is a biologic used in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). Remicade is given as an intravenous infusion while our only competitor (Humira) is given as a subcutaneous injection.

From 2009 we have focused on both establishing Remicade in the treatment pathway for CD and differentiating Remicade from the competition.

Our objectives have been on growth, market share and campaign implementation.

Three core initiatives have been consistently evolved throughout 2009–20011 to enable MSD to achieve our objectives. These are:

  • Market access propositions
    - Identification of service issues and solutions, "lean" solutions to capacity issuesand commercial proposition
  • Medical education
    - Best practice, clinical and non-clinical developments
  • Promotional campaign
    - Focusing on establishing treatment pathways and improving patient outcomes

Our learnings include the importance of customer insight in the development and evolution of these core initiatives. The patient should be at the centre of the core campaign with the focus on improving patient outcomes and experience. This should be consistent in our market access and medical propositions and also our sales promotional campaign.

Incorporating the sales team in the development of the campaigns has ensured "buy-in" and has resulted in effective implementation of the campaign.

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics